NEWPORT BEACH, Calif., September 9, 2013: CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will host the “Drug Development and Clinical Trial Participation – A Webinar for the Rare Disease Community” on September 13, 2013 at 2 p.m. EST. The webinar is an opportunity for parents to learn about the drug development process – from the pre-clinical phase to the clinical phase to the post approval phase and the regulatory process guiding these phases – from industry experts.
The webinar presenters are:
· Carl Morris, Ph.D., Director, Protein Therapeutics and Muscle Biology, Pfizer Rare Disease Research Unit
· Lawrence Charnas, M.D., Ph.D., Director & Head, Discovery Medicine at Shire plc
· Jennifer Eaddy, Associate Director, Regulatory Affairs, Genzyme
The session will be moderated by Michael Kelly, Ph.D., Chief Scientific Officer at CureDuchenne.
Duchenne is a progressive muscle-wasting disease that impact 1 in 3,500 boys. Boys with Duchenne are usually diagnosed before the age of 5, in a wheelchair by age 12 and most don’t survive their mid-20s. There is currently no cure for Duchenne. CureDuchenne has funded seven research projects that have gone into human clinical trials.
To register for the “Drug Development and Clinical Trial Participation” webinar on September 13, click here.
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide.
CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.